Focal Segmental Glomerulosclerosis
Pipeline by Development Stage
Drug Modality Breakdown
Nephrology is a $36.6B mature market dominated by cardiometabolic crossover drugs with limited pure renal innovation.
Key Trends
- GLP-1 agonists and SGLT2 inhibitors dominate (69% of spending) due to dual cardio-renal benefits
- Patent cliffs approaching 2026-2030 create generic conversion risk for blockbuster franchises
- Pipeline activity remains robust (2,785 trials) but concentrated in early-phase basic research
Career Verdict
Nephrology offers stable employment in commercial and medical affairs roles, but limited growth upside due to mature blockbuster dependency and declining pure renal research focus.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | OZEMPIC (semaglutide) | Novo Nordisk | $9.2B | 25% | Peak | Stable | 12.4yr |
| 2 | JARDIANCE (empagliflozin) | Boehringer Ingelheim | $8.8B | 24% | Peak | Stable | 8.6yr |
| 3 | TRULICITY (dulaglutide) | Eli Lilly and Company | $7.4B | 20% | Peak | Stable | |
| 4 | FARXIGA (dapagliflozin) | AstraZeneca | $4.3B | 12% | Peak | Stable | 15.4yr |
Drug Class Breakdown
cardiometabolic dominance
cardioprotective expansion
heart failure crossover
overactive bladder niche
declining relevance
Career Outlook
StableNephrology careers are stable but not expanding; the field is supported by blockbuster drugs (GLP-1s, SGLT2i) that face patent cliffs between 2026–2041, creating near-term employment security but long-term uncertainty. Commercial and medical affairs roles dominate hiring, while R&D investment is limited to niche mechanisms (complement inhibition, gene therapy). Career progression depends on specialization in medtech, diagnostics, or orphan nephrology rather than traditional pharma blockbuster development.
Breaking In
Target medtech platforms (Outset, Fresenius) or biotech innovators (Vertex, Calyxo) over traditional pharma; nephrology offers job stability and clinical depth but limited growth trajectory in pure pharmaceutical roles.
For Experienced Professionals
Leverage cardiometabolic expertise to span diabetes, CKD, and HF franchises; position for transition to orphan nephrology (ADPKD, FSGS, IgA) where innovation and valuation multiples are highest.
In-Demand Skills
Best For
Hiring Landscape
Nephrology hiring is concentrated in commercial roles (58 positions, $108K avg) and medical affairs (12 positions, $330K avg), reflecting mature market dynamics. Top hiring companies are innovative platforms (Vertex: 41 jobs) and medtech (Outset: 21 jobs), not traditional pharma. Salary compression in commercial roles suggests commoditization.
Top Hiring Companies
By Department
Hiring favors medtech and biotech platforms over traditional pharma; medical affairs offers premium compensation but limited volume; commercial roles are abundant but underpaid relative to other therapeutic areas.
On Market (1)
Approved therapies currently available
Competitive Landscape
11 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Clinical Trials (14)
Total enrollment: 2,251 patients across 14 trials
Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan
A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)
Related Jobs in Nephrology
Patient Analytics Senior Manager
Medical Affairs Associate Medical Director - Nephrology
Executive Director, Clinical Development Nephrology
Senior Director, Market Enablement
Clinical Account Manager (Cherry Hill, NJ)
Market Research Associate Director
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.